CCND1 and cancer: Oncrasin-72 exerts its activity by inhibiting C-terminal domain phosphorylation of RNA polymerase II in sensitive human cancer cells, thereby activating JNK, suppressing JAK2/STAT3 phosphorylation, and reducing cyclin D1 expression.